Pharma Patent 'Thickets' Tripled Duration of Drug Exclusivity Since 1990, JAMA Study Finds
A study in JAMA reveals that pharmaceutical firms tripled secondary patent filings on small-molecule drugs between 1990 and 2019, extending market exclusivity from two years to over six.
